Immunome (IMNM) Free Cash Flow (2019 - 2026)

Immunome has reported Free Cash Flow for 8 years, with the latest figure at -$59.8 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 11.41% year-over-year to -$59.8 million; the trailing twelve-month figure through Mar 2026 stood at -$198.0 million (down 28.67% YoY), and the FY2025 full-year result was -$191.9 million, down 68.95% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$59.8 million, down from -$43.3 million in the prior quarter.
• The five-year high for Free Cash Flow was $24.1 million in Q1 2023, with the low at -$59.8 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$23.7 million across 5 years, with a median of -$17.8 million in 2023.
• Annual changes were most pronounced in 2023 — Free Cash Flow jumped 477.11% — and 2025, when it plunged 302.33%.
• Immunome's Free Cash Flow stood at -$6.8 million in 2022, then sank by 163.63% to -$17.8 million in 2023, then slumped by 148.9% to -$44.3 million in 2024, then rose by 2.37% to -$43.3 million in 2025, then slumped by 38.12% to -$59.8 million in 2026.
• The last three Free Cash Flow figures came in at -$59.8 million (Q1 2026), -$43.3 million (Q4 2025), and -$44.9 million (Q3 2025), per Business Quant data.